

Kirk A. Cullimore proposes the following substitute bill:

Controlled Substance Modifications

2025 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Jennifer Dailey-Provost

Senate Sponsor: Kirk A. Cullimore

LONG TITLE

General Description:

This bill amends provisions related to the Controlled Substances Act.

Highlighted Provisions:

This bill:

- classifies amanita muscaria as a controlled substance; and
- provides for the automatic rescheduling of a certain type of psilocybin if rescheduled by the federal government.

Money Appropriated in this Bill:

None

Other Special Clauses:

None

Utah Code Sections Affected:

AMENDS:

58-37-4, as last amended by Laws of Utah 2024, Chapter 298

Be it enacted by the Legislature of the state of Utah:

Section 1. Section **58-37-4** is amended to read:

58-37-4 . Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules.

(1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which consist of substances listed in this section.

(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated:

(a) Schedule I:

- (i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of

- 30 isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
31 salts is possible within the specific chemical designation:
- 32 (A) Acetyl-alpha-methylfentanyl
33 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
- 34 (B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
- 35 (C) Acetylmethadol;
- 36 (D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);
- 37 (E) Allylprodine;
- 38 (F) Alphacetylmethadol, except levo-alphacetylmethadol also known as
39 levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
- 40 (G) Alphameprodine;
- 41 (H) Alphamethadol;
- 42 (I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
43 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
- 44 (J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
45 piperidinyl]-N-phenylpropanamide);
- 46 (K) Benzylpiperazine;
- 47 (L) Benzethidine;
- 48 (M) Betacetylmethadol;
- 49 (N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
50 piperidinyl]-N-phenylpropanamide);
- 51 (O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
52 phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
- 53 (P) Betameprodine;
- 54 (Q) Betamethadol;
- 55 (R) Betaprodine;
- 56 (S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
- 57 (T) Clonitazene;
- 58 (U) Cyclopropyl fentanyl
59 (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
- 60 (V) Dextromoramide;
- 61 (W) Diampromide;
- 62 (X) Diethylthiambutene;
- 63 (Y) Difenoxin;

- 64 (Z) Dimenoxadol;
- 65 (AA) Dimepheptanol;
- 66 (BB) Dimethylthiambutene;
- 67 (CC) Dioxaphetyl butyrate;
- 68 (DD) Dipipanone;
- 69 (EE) Ethylmethylthiambutene;
- 70 (FF) Etizolam
- 71 (1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
- 72 (GG) Etonitazene;
- 73 (HH) Etoxeridine;
- 74 (II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
- 75 furan-2-carboxamide);
- 76 (JJ) Furethidine;
- 77 (KK) Hydroxypethidine;
- 78 (LL) Ketobemidone;
- 79 (MM) Levomoramide;
- 80 (NN) Levophenacilmorphan;
- 81 (OO) Methoxyacetyl fentanyl
- 82 (2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);
- 83 (PP) Morpheridine;
- 84 (QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 85 (RR) Noracymethadol;
- 86 (SS) Norlevorphanol;
- 87 (TT) Normethadone;
- 88 (UU) Norpipanone;
- 89 (VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
- 90 propanamide);
- 91 (WW) Para-fluoroisobutyryl fentanyl
- 92 (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
- 93 (XX) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 94 (YY) Phenadoxone;
- 95 (ZZ) Phenampromide;
- 96 (AAA) Phenomorphan;
- 97 (BBB) Phenoperidine;

- 98 (CCC) Piritramide;
- 99 (DDD) Proheptazine;
- 100 (EEE) Properidine;
- 101 (FFF) Propiram;
- 102 (GGG) Racemoramide;
- 103 (HHH) Tetrahydrofuran fentanyl
(N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
- 104 (III) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
- 105 (JJJ) Tilidine;
- 106 (KKK) Trimeperidine;
- 107 (LLL) 3-methylfentanyl, including the optical and geometric isomers
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);
- 108 (MMM) 3-methylthiofentanyl
(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 109 (NNN) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also
known as U-47700; and
- 110 (OOO) 4-cyano CUMYL-BUTINACA.
- 111 (ii) Unless specifically excepted or unless listed in another schedule, any of the
112 following opium derivatives, their salts, isomers, and salts of isomers when the
113 existence of the salts, isomers, and salts of isomers is possible within the specific
114 chemical designation:
- 115 (A) Acetorphine;
- 116 (B) Acetyldihydrocodeine;
- 117 (C) Benzylmorphine;
- 118 (D) Codeine methylbromide;
- 119 (E) Codeine-N-Oxide;
- 120 (F) Cyprenorphine;
- 121 (G) Desomorphine;
- 122 (H) Dihydromorphine;
- 123 (I) Drotebanol;
- 124 (J) Etorphine (except hydrochloride salt);
- 125 (K) Heroin;
- 126 (L) Hydromorphanol;
- 127 (M) Methyldesorphine;
- 128
- 129
- 130
- 131

- 132 (N) Methylhydromorphine;
133 (O) Morphine methylbromide;
134 (P) Morphine methylsulfonate;
135 (Q) Morphine-N-Oxide;
136 (R) Myrophine;
137 (S) Nicocodeine;
138 (T) Nicomorphine;
139 (U) Normorphine;
140 (V) Pholcodine; and
141 (W) Thebacon.
- 142 (iii) Unless specifically excepted or unless listed in another schedule, any material,
143 compound, mixture, or preparation which contains any quantity of the following
144 hallucinogenic substances, or which contains any of their salts, isomers, and salts
145 of isomers when the existence of the salts, isomers, and salts of isomers is possible
146 within the specific chemical designation; as used in this Subsection (2)(a)(iii)
147 only, "isomer" includes the optical, position, and geometric isomers:
- 148 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α
149 -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;
150 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
151 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;
152 (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:
153 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB;
154 2C-B, Nexus;
155 (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy- α
156 -methylphenethylamine; 2,5-DMA;
157 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
158 (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy- α
159 -methylphenethylamine; paramethoxyamphetamine, PMA;
160 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
161 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
162 4-methyl-2,5-dimethoxy- α -methylphenethylamine; "DOM"; and "STP";
163 (I) 3,4-methylenedioxy amphetamine;
164 (J) 3,4-methylenedioxymethamphetamine (MDMA);
165 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-

- 166 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE,
167 MDEA;
- 168 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
169 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy
170 MDA;
- 171 (M) 3,4,5-trimethoxy amphetamine;
- 172 (N) Bufotenine, some trade and other names: 3-(β
173 -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol;
174 N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
- 175 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
- 176 (P) Dimethyltryptamine, some trade or other names: DMT;
- 177 (Q) Ibogaine, some trade and other names: 7-Ethyl-6,6β
178 ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2]
179 azepino [5,4-b] indole; Tabernanthe iboga;
- 180 (R) Lysergic acid diethylamide;
- 181 (S) Marijuana;
- 182 (T) Mescaline;
- 183 (U) Parahexyl, some trade or other names:
184 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
185 Synhexyl;
- 186 (V) Peyote, meaning all parts of the plant presently classified botanically as
187 *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any
188 extract from any part of such plant, and every compound, manufacture, salts,
189 derivative, mixture, or preparation of such plant, its seeds or extracts
190 (Interprets 21 USC 812(c), Schedule I(c) (12));
- 191 (W) N-ethyl-3-piperidyl benzilate;
- 192 (X) N-methyl-3-piperidyl benzilate;
- 193 (Y) Psilocybin, except as provided in Subsection (3);
- 194 (Z) Psilocyn;
- 195 (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus *Cannabis*
196 (*cannabis* plant), except for marijuana as defined in Subsection 58-37-2
197 (1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the
198 *cannabis* plant, or in the resinous extractives of *Cannabis*, sp. and/or synthetic
199 substances, derivatives, and their isomers with similar chemical structure and

- 200 pharmacological activity to those substances contained in the plant, such as the
201 following: $\Delta 1$ cis or trans tetrahydrocannabinol, and their optical isomers $\Delta 6$ cis or
202 trans tetrahydrocannabinol, and their optical isomers $\Delta 3,4$ cis or trans
203 tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
204 substances is not internationally standardized, compounds of these structures,
205 regardless of numerical designation of atomic positions covered;
- 206 (BB) Ethylamine analog of phencyclidine, some trade or other names:
207 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
208 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
- 209 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
210 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
- 211 (DD) Thiophene analog of phencyclidine, some trade or other names:
212 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine,
213 TPCP, TCP; and
- 214 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
- 215 (iv) Unless specifically excepted or unless listed in another schedule, any material
216 compound, mixture, or preparation which contains any quantity of the following
217 substances having a depressant effect on the central nervous system, including its
218 salts, isomers, and salts of isomers when the existence of the salts, isomers, and
219 salts of isomers is possible within the specific chemical designation:
- 220 (A) Mecloqualone; and
221 (B) Methaqualone.
- 222 (v) Any material, compound, mixture, or preparation containing any quantity of the
223 following substances having a stimulant effect on the central nervous system,
224 including their salts, isomers, and salts of isomers:
- 225 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline;
226 or 4,5-dihydro-5-phenyl-2-oxazolamine;
- 227 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
228 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
- 229 (C) Fenethylamine;
- 230 (D) Methcathinone, some other names: 2-(methylamino)-propionophenone;
231 alpha-(methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one;
232 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone;
233 N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432,

- 234 its salts, optical isomers, and salts of optical isomers;
- 235 (E) (\pm)cis-4-methylaminorex ((\pm)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 236 (F) N-ethylamphetamine; and
- 237 (G) N,N-dimethylamphetamine, also known as
- 238 N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
- 239 (vi) Any material, compound, mixture, or preparation which contains any quantity of
- 240 the following substances, including their optical isomers, salts, and salts of
- 241 isomers, subject to temporary emergency scheduling:
- 242 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
- 243 (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thienylfentanyl).
- 244 (vii) Unless specifically excepted or unless listed in another schedule, any material,
- 245 compound, mixture, or preparation which contains any quantity of gamma
- 246 hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and
- 247 salts of isomers.
- 248 (b) Schedule II:
- 249 (i) Unless specifically excepted or unless listed in another schedule, any of the
- 250 following substances whether produced directly or indirectly by extraction from
- 251 substances of vegetable origin, or independently by means of chemical synthesis,
- 252 or by a combination of extraction and chemical synthesis:
- 253 (A) Opium and opiate, and any salt, compound, derivative, or preparation of
- 254 opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene,
- 255 naloxone, and naltrexone, and their respective salts, but including:
- 256 (I) Raw opium;
- 257 (II) Opium extracts;
- 258 (III) Opium fluid;
- 259 (IV) Powdered opium;
- 260 (V) Granulated opium;
- 261 (VI) Tincture of opium;
- 262 (VII) Codeine;
- 263 (VIII) Ethylmorphine;
- 264 (IX) Etorphine hydrochloride;
- 265 (X) Hydrocodone;
- 266 (XI) Hydromorphone;
- 267 (XII) Metopon;

- 268 (XIII) Morphine;
- 269 (XIV) Oxycodone;
- 270 (XV) Oxymorphone; and
- 271 (XVI) Thebaine;
- 272 (B) Any salt, compound, derivative, or preparation which is chemically equivalent
- 273 or identical with any of the substances referred to in Subsection (2)(b)(i)(A),
- 274 except that these substances may not include the isoquinoline alkaloids of
- 275 opium;
- 276 (C) Opium poppy and poppy straw;
- 277 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves,
- 278 and any salt, compound, derivative, or preparation which is chemically
- 279 equivalent or identical with any of these substances, and includes cocaine and
- 280 ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives,
- 281 whether derived from the coca plant or synthetically produced, except the
- 282 substances may not include decocainized coca leaves or extraction of coca
- 283 leaves, which extractions do not contain cocaine or ecgonine; and
- 284 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in
- 285 either liquid, solid, or powder form which contains the phenanthrene alkaloids
- 286 of the opium poppy.
- 287 (ii) Unless specifically excepted or unless listed in another schedule, any of the
- 288 following opiates, including their isomers, esters, ethers, salts, and salts of
- 289 isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
- 290 salts is possible within the specific chemical designation, except dextroprhan and
- 291 levopropoxyphene:
- 292 (A) Alfentanil;
- 293 (B) Alphaprodine;
- 294 (C) Anileridine;
- 295 (D) Bezitramide;
- 296 (E) Bulk dextropropoxyphene (nondosage forms);
- 297 (F) Carfentanil;
- 298 (G) Dihydrocodeine;
- 299 (H) Diphenoxylate;
- 300 (I) Fentanyl;
- 301 (J) Isomethadone;

- 302 (K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol,
303 levomethadyl acetate, or LAAM;
- 304 (L) Levomethorphan;
- 305 (M) Levorphanol;
- 306 (N) Metazocine;
- 307 (O) Methadone;
- 308 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
- 309 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1,
310 1-diphenylpropane-carboxylic acid;
- 311 (R) Pethidine (meperidine);
- 312 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 313 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 314 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 315 (V) Phenazocine;
- 316 (W) Piminodine;
- 317 (X) Racemethorphan;
- 318 (Y) Racemorphan;
- 319 (Z) Remifentanil; and
- 320 (AA) Sufentanil.
- 321 (iii) Unless specifically excepted or unless listed in another schedule, any material,
322 compound, mixture, or preparation which contains any quantity of the following
323 substances having a stimulant effect on the central nervous system:
- 324 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 325 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
- 326 (C) Phenmetrazine and its salts; and
- 327 (D) Methylphenidate.
- 328 (iv) Unless specifically excepted or unless listed in another schedule, any material,
329 compound, mixture, or preparation which contains any quantity of the following
330 substances having a depressant effect on the central nervous system, including its
331 salts, isomers, and salts of isomers when the existence of the salts, isomers, and
332 salts of isomers is possible within the specific chemical designation:
- 333 (A) Amobarbital;
- 334 (B) Glutethimide;
- 335 (C) Pentobarbital;

- 336 (D) Phencyclidine;
- 337 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
- 338 1-piperidinocyclohexanecarbonitrile (PCC); and
- 339 (F) Secobarbital.
- 340 (v)(A) Unless specifically excepted or unless listed in another schedule, any
- 341 material, compound, mixture, or preparation which contains any quantity of
- 342 Phenylacetone.
- 343 (B) Some of these substances may be known by trade or other names:
- 344 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
- 345 (vi) Nabilone, another name for nabilone: (\pm
- 346)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
- 347 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
- 348 (vii) A drug product or preparation that contains any component of marijuana,
- 349 including tetrahydrocannabinol, and is approved by the United States Food and
- 350 Drug Administration and scheduled by the Drug Enforcement Administration in
- 351 Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 352 (c) Schedule III:
- 353 (i) Unless specifically excepted or unless listed in another schedule, any material,
- 354 compound, mixture, or preparation which contains any quantity of the following
- 355 substances having a stimulant effect on the central nervous system, including its
- 356 salts, isomers whether optical, position, or geometric, and salts of the isomers
- 357 when the existence of the salts, isomers, and salts of isomers is possible within the
- 358 specific chemical designation:
- 359 (A) Those compounds, mixtures, or preparations in dosage unit form containing
- 360 any stimulant substances listed in Schedule II, which compounds, mixtures, or
- 361 preparations were listed on August 25, 1971, as excepted compounds under
- 362 Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other
- 363 drug of the quantitative composition shown in that list for those drugs or which
- 364 is the same except that it contains a lesser quantity of controlled substances;
- 365 (B) Benzphetamine;
- 366 (C) Chlorphentermine;
- 367 (D) Clortermine; and
- 368 (E) Phendimetrazine.
- 369 (ii) Unless specifically excepted or unless listed in another schedule, any material,

- 370 compound, mixture, or preparation which contains any quantity of the following
371 substances having a depressant effect on the central nervous system:
- 372 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
373 pentobarbital, or any salt of any of them, and one or more other active
374 medicinal ingredients which are not listed in any schedule;
- 375 (B) Any suppository dosage form containing amobarbital, secobarbital, or
376 pentobarbital, or any salt of any of these drugs which is approved by the United
377 States Food and Drug Administration for marketing only as a suppository;
- 378 (C) Any substance which contains any quantity of a derivative of barbituric acid
379 or any salt of any of them;
- 380 (D) Chlorhexadol;
- 381 (E) Buprenorphine;
- 382 (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
383 isomers, and salts of isomers, for which an application is approved under the
384 federal Food, Drug, and Cosmetic Act, Section 505;
- 385 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for
386 ketamine: \pm -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
- 387 (H) Lysergic acid;
- 388 (I) Lysergic acid amide;
- 389 (J) Methyprylon;
- 390 (K) Sulfondiethylmethane;
- 391 (L) Sulfonethylmethane;
- 392 (M) Sulfonmethane; and
- 393 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for
394 a tiletamine-zolazepam combination product: Telazol, some trade or other
395 names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade
396 or other names for zolazepam:
397 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]
398 [1,4]-diazepin-7(1H)-one, flupyrazapon.
- 399 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in
400 a U.S. Food and Drug Administration approved drug product, some other names
401 for dronabinol:
402 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol,
403 or (-)-delta-9-(trans)-tetrahydrocannabinol.

- 404 (iv) Nalorphine.
- 405 (v) Unless specifically excepted or unless listed in another schedule, any material,
406 compound, mixture, or preparation containing limited quantities of any of the
407 following narcotic drugs, or their salts calculated as the free anhydrous base or
408 alkaloid:
- 409 (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
410 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline
411 alkaloid of opium;
- 412 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
413 milligrams per dosage unit, with one or more active non-narcotic ingredients in
414 recognized therapeutic amounts;
- 415 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
416 more than 15 milligrams per dosage unit, with a fourfold or greater quantity of
417 an isoquinoline alkaloid of opium;
- 418 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
419 more than 15 milligrams per dosage unit, with one or more active, non-narcotic
420 ingredients in recognized therapeutic amounts;
- 421 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more
422 than 90 milligrams per dosage unit, with one or more active non-narcotic
423 ingredients in recognized therapeutic amounts;
- 424 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
425 than 15 milligrams per dosage unit, with one or more active, non-narcotic
426 ingredients in recognized therapeutic amounts;
- 427 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
428 or not more than 25 milligrams per dosage unit, with one or more active,
429 non-narcotic ingredients in recognized therapeutic amounts; and
- 430 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
431 with one or more active, non-narcotic ingredients in recognized therapeutic
432 amounts.
- 433 (vi) Unless specifically excepted or unless listed in another schedule, anabolic
434 steroids including any of the following or any isomer, ester, salt, or derivative of
435 the following that promotes muscle growth:
- 436 (A) Boldenone;
- 437 (B) Chlorotestosterone (4-chlortestosterone);

- 438 (C) Clostebol;
- 439 (D) Dehydrochlormethyltestosterone;
- 440 (E) Dihydrotestosterone (4-dihydrotestosterone);
- 441 (F) Drostanolone;
- 442 (G) Ethylestrenol;
- 443 (H) Fluoxymesterone;
- 444 (I) Formebolone (formebolone);
- 445 (J) Mesterolone;
- 446 (K) Methandienone;
- 447 (L) Methandranone;
- 448 (M) Methandriol;
- 449 (N) Methandrostenolone;
- 450 (O) Methenolone;
- 451 (P) Methyltestosterone;
- 452 (Q) Mibolerone;
- 453 (R) Nandrolone;
- 454 (S) Norethandrolone;
- 455 (T) Oxandrolone;
- 456 (U) Oxymesterone;
- 457 (V) Oxymetholone;
- 458 (W) Stanolone;
- 459 (X) Stanozolol;
- 460 (Y) Testolactone;
- 461 (Z) Testosterone; and
- 462 (AA) Trenbolone.
- 463 (vii) Anabolic steroids expressly intended for administration through implants to
- 464 cattle or other nonhuman species, and approved by the Secretary of Health and
- 465 Human Services for use, may not be classified as a controlled substance.
- 466 (viii) A drug product or preparation that contains any component of marijuana,
- 467 including tetrahydrocannabinol, and is approved by the United States Food and
- 468 Drug Administration and scheduled by the Drug Enforcement Administration in
- 469 Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 470 (ix) Nabiximols.
- 471 (x) Amanita Muscaria.

- 472 (d) Schedule IV:
- 473 (i) Unless specifically excepted or unless listed in another schedule, any material,
474 compound, mixture, or preparation containing not more than 1 milligram of
475 difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or
476 any salts of any of them.
- 477 (ii) Unless specifically excepted or unless listed in another schedule, any material,
478 compound, mixture, or preparation which contains any quantity of the following
479 substances, including its salts, isomers, and salts of isomers when the existence of
480 the salts, isomers, and salts of isomers is possible within the specific chemical
481 designation:
- 482 (A) Alprazolam;
 - 483 (B) Barbital;
 - 484 (C) Bromazepam;
 - 485 (D) Butorphanol;
 - 486 (E) Camazepam;
 - 487 (F) Carisoprodol;
 - 488 (G) Chloral betaine;
 - 489 (H) Chloral hydrate;
 - 490 (I) Chlordiazepoxide;
 - 491 (J) Clobazam;
 - 492 (K) Clonazepam;
 - 493 (L) Clorazepate;
 - 494 (M) Clotiazepam;
 - 495 (N) Cloxazolam;
 - 496 (O) Delorazepam;
 - 497 (P) Diazepam;
 - 498 (Q) Dichloralphenazone;
 - 499 (R) Estazolam;
 - 500 (S) Ethchlorvynol;
 - 501 (T) Ethinamate;
 - 502 (U) Ethyl loflazepate;
 - 503 (V) Fludiazepam;
 - 504 (W) Flunitrazepam;
 - 505 (X) Flurazepam;

- 506 (Y) Halazepam;
507 (Z) Haloxazolam;
508 (AA) Ketazolam;
509 (BB) Loprazolam;
510 (CC) Lorazepam;
511 (DD) Lormetazepam;
512 (EE) Mebutamate;
513 (FF) Medazepam;
514 (GG) Meprobamate;
515 (HH) Methohexital;
516 (II) Methylphenobarbital (mephobarbital);
517 (JJ) Midazolam;
518 (KK) Nimetazepam;
519 (LL) Nitrazepam;
520 (MM) Nordiazepam;
521 (NN) Oxazepam;
522 (OO) Oxazolam;
523 (PP) Paraldehyde;
524 (QQ) Pentazocine;
525 (RR) Petrichloral;
526 (SS) Phenobarbital;
527 (TT) Pinazepam;
528 (UU) Prazepam;
529 (VV) Quazepam;
530 (WW) Temazepam;
531 (XX) Tetrazepam;
532 (YY) Tramadol;
533 (ZZ) Triazolam;
534 (AAA) Zaleplon; and
535 (BBB) Zolpidem.
- 536 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
537 any quantity of the following substances, including its salts, isomers whether
538 optical, position, or geometric, and salts of the isomers when the existence of the
539 salts, isomers, and salts of isomers is possible.

- 540 (iv) Unless specifically excepted or unless listed in another schedule, any material,
541 compound, mixture, or preparation which contains any quantity of the following
542 substances having a stimulant effect on the central nervous system, including its
543 salts, isomers whether optical, position, or geometric isomers, and salts of the
544 isomers when the existence of the salts, isomers, and salts of isomers is possible
545 within the specific chemical designation:
- 546 (A) Cathine ((+)-norpseudoephedrine);
 - 547 (B) Diethylpropion;
 - 548 (C) Fencamfamine;
 - 549 (D) Fenproporex;
 - 550 (E) Mazindol;
 - 551 (F) Mefenorex;
 - 552 (G) Modafinil;
 - 553 (H) Pemoline, including organometallic complexes and chelates thereof;
 - 554 (I) Phentermine;
 - 555 (J) Pipradrol;
 - 556 (K) Sibutramine; and
 - 557 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
- 558 (v) Unless specifically excepted or unless listed in another schedule, any material,
559 compound, mixture, or preparation which contains any quantity of
560 dextropropoxyphene (alpha-(+)-4-dimethylamino-1,
561 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
- 562 (vi) A drug product or preparation that contains any component of marijuana and is
563 approved by the United States Food and Drug Administration and scheduled by
564 the Drug Enforcement Administration in Schedule IV of the federal Controlled
565 Substances Act, Title II, P.L. 91-513.
- 566 (e) Schedule V:
- 567 (i) Any compound, mixture, or preparation containing any of the following limited
568 quantities of narcotic drugs, or their salts calculated as the free anhydrous base or
569 alkaloid, which includes one or more non-narcotic active medicinal ingredients in
570 sufficient proportion to confer upon the compound, mixture, or preparation
571 valuable medicinal qualities other than those possessed by the narcotic drug alone:
 - 572 (A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
 - 573 (B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100

- 574 grams;
- 575 (C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
- 576 grams;
- 577 (D) not more than 2.5 milligrams of diphenoxylate and not less than 25
- 578 micrograms of atropine sulfate per dosage unit;
- 579 (E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
- 580 (F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
- 581 atropine sulfate per dosage unit; and
- 582 (G) unless specifically exempted or excluded or unless listed in another schedule,
- 583 any material, compound, mixture, or preparation which contains Pyrovalerone
- 584 having a stimulant effect on the central nervous system, including its salts,
- 585 isomers, and salts of isomers.
- 586 (ii) A drug product or preparation that contains any component of marijuana,
- 587 including cannabidiol, and is approved by the United States Food and Drug
- 588 Administration and scheduled by the Drug Enforcement Administration in
- 589 Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 590 (iii) Gabapentin.
- 591 (3) If the federal government schedules the pharmaceutical composition of
- 592 crystallinepolymorph psilocybin in a schedule that is not schedule I, that composition is
- 593 deemed scheduled under this section in the same schedule that the composition is
- 594 scheduled under 21 U.S.C. Sec. 812 and 21 C.F.R. Sec. 1308.14.

595 **Section 2. Effective Date.**

596 This bill takes effect on May 7, 2025.